Prediction of ESRD in Pauci-immune Necrotizing Glomerulonephritis: Quantitative Histomorphometric Assessment and Serum Creatinine. by Day, CJ et al.
 
 
University of Birmingham
Prediction of ESRD in Pauci-immune Necrotizing
Glomerulonephritis: Quantitative
Histomorphometric Assessment and Serum
Creatinine.
Day, CJ; Howie, AJ; Nightingale, Peter; Shabir, Shazia; Adu, Dwomoa; Savage, Caroline;
Hewins, Peter
DOI:
10.1053/j.ajkd.2009.10.047
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Day, CJ, Howie, AJ, Nightingale, P, Shabir, S, Adu, D, Savage, C & Hewins, P 2010, 'Prediction of ESRD in
Pauci-immune Necrotizing Glomerulonephritis: Quantitative Histomorphometric Assessment and Serum
Creatinine.', American Journal of Kidney Diseases, vol. 55, no. 2, pp. 250-258.
https://doi.org/10.1053/j.ajkd.2009.10.047
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
Prediction of ESRD in Pauci-immune Necrotizing
Glomerulonephritis: Quantitative Histomorphometric
Assessment and Serum Creatinine
Clara J. Day1, Alec J. Howie2, Peter Nightingale3,⁎, Shazia Shabir1, Dwomoa Adu1, Caroline
O. Savage4, and Peter Hewins1,4
1Department of Nephrology, University Hospitals Birmingham NHS Foundation Trust, Birmingham,
UK.
2Department of Pathology, University College London, UK.
3Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation
Trust, Birmingham, UK.
4School of Immunity & Infection, College of Medical and Dental Sciences, University of Birmingham,
Birmingham, UK.
Abstract
Background—Clinical and pathologic features that predict outcome have important potential
application in patients with pauci-immune necrotizing glomerulonephritis (usually antineutrophil
cytoplasmic antibody–associated vasculitis). This study examines the predictive value of simple
quantitative renal histologic measurements in a large cohort with extended follow-up.
Study Design—Cohort study.
Setting & Participants—390 consecutive patients with pauci-immune necrotizing
glomerulonephritis at a single hospital (1983-2002); 90 patients underwent repeated kidney biopsy
during follow-up.
Predictors—Age and serum creatinine concentration at biopsy, antineutrophil cytoplasmic
antibody specificity, percentage of normal glomeruli, percentage of glomeruli with active lesions,
and index of chronic damage (quantitative measurement of established cortical damage) in the initial
kidney biopsy for all patients. The same factors were assessed in both biopsy specimens for patients
undergoing an additional biopsy.
Outcomes & Measurements—End-stage renal disease and patient survival.
Results—Mortality at 1 and 5 years was 23% and 40%, respectively: standardized mortality ratio,
4.74 (95% CI, 3.62-6.32). End-stage renal disease was reached by 14% and 18% at 1 and 5 years,
respectively. In multivariable analysis, serum creatinine level at biopsy and percentage of normal
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glomeruli in the initial biopsy specimen were the best predictors of kidney survival. C Statistics were
0.80 for creatinine level alone and 0.83 for creatinine level with normal glomeruli. In patients
undergoing an additional biopsy, rapid progression in the index of chronic damage and serum
creatinine level at the second biopsy were associated with kidney survival in multivariable analysis.
Limitations—Retrospective analysis. External validity of the index of chronic damage requires
further assessment. Selection bias may influence repeated biopsy analyses.
Conclusions—Serum creatinine level at biopsy best predicts kidney survival in patients with pauci-
immune necrotizing glomerulonephritis overall.
Index Words
Vasculitis; necrotizing glomerulonephritis; antineutrophil cytoplasm autoantibody; kidney biopsy;
end-stage renal disease (ESRD)
Wegener granulomatosis and microscopic polyangiitis are antineutrophil cytoplasmic antibody
(ANCA)-associated small-vessel vasculitides that cause rapidly progressive pauci-immune
necrotizing glomerulonephritis. The routine use of immunosuppressive therapies has
dramatically improved prognosis, and randomized trials have established evidence-based
treatment. Nevertheless, significant morbidity and mortality are still prevalent as a result of
both disease and treatment, particularly in the elderly.
Previous reports have correlated presenting serum creatinine level with kidney outcome in
patients with pauci-immune necrotizing glomerulonephritis; however, at least some patients
with severe kidney disease recover independent kidney function when treated appropriately.
Whereas the primary purpose of a kidney biopsy is diagnostic, it not infrequently reveals a
combination of acute and chronic lesions that may have prognostic relevance. A number of
studies have highlighted the value of measurements of glomerular morphologic characteristics
in this context; however, assessments of tubular and interstitial damage frequently are
semiquantitative and may be subject to greater variability. Moreover, assessments that involve
many components are not necessarily readily applicable in routine practice outside of specialist
centers.
We have previously described a simple morphometric measure of chronic damage that assesses
the entire area of renal cortex in a biopsy specimen and have shown that the index predicts
kidney survival in various settings. We hypothesized that the index would predict kidney
survival in patients with pauci-immune necrotizing glomerulonephritis and, in this study, set
out to test its performance in comparison to quantitative measurements of glomerular
morphologic characteristics in a retrospective cohort of 390 patients sampled at a single center.
Methods
Clinical Data
All patients at the Queen Elizabeth Hospital, Birmingham, UK, with a diagnosis of pauci-
immune necrotizing glomerulonephritis by kidney biopsy between 1983 and 2002 were
included. Clinical data were obtained from patient records (hospital and general practice). Date
and cause of death were obtained from public records and death certificates. Serum creatinine
was measured at the time of biopsy or before the initiation of acute dialysis therapy if this
occurred before the biopsy was performed. Biopsies ordinarily were performed before
administration of immunosuppressive therapy or shortly thereafter in exceptional cases.
Repeated biopsies ordinarily were performed before escalation of immunosuppression.
Patients were defined as reaching the end point of end-stage renal disease (ESRD) when they
required permanent renal replacement therapy, in other words, long-term dialysis therapy or
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transplant. Patients who required acute dialysis at presentation or relapse, but who recovered
independent kidney function after treatment, were not classified as reaching the end point.
Time to the end point was defined as time elapsed between biopsy (time zero) and either death
or initiation of permanent renal replacement therapy. The status of all patients was determined
at the end of 2004. Research was conducted in accordance with the Declaration of Helsinki.
During the period studied, standard treatments used were cyclophosphamide (either pulsed
intravenous or daily oral) for active disease with high-dose prednisolone (1 mg/kg) tapered
over 2-3 months. On remission and after 3 to 6 months of treatment, patients were switched to
maintenance therapy with azathioprine and low-dose prednisolone. Few patients stopped the
medication. Those with either dialysis-requiring acute kidney failure or pulmonary hemorrhage
were treated using plasma exchange.
Death certificates were available for 186 of 214 patients who died. Forty-three patients died
within 3 months of diagnosis, and certified causes of death in these cases were kidney failure,
vasculitis, or infection. We classified all deaths during this period as related to active vasculitis
because infection was presumed to be secondary to intensive immunosuppression. Deaths
attributed to infection > 3 months after diagnosis were coded separately.
Measurement of Index of Chronic Damage and Other Pathologic Investigations
Stored slides of renal biopsy specimens were examined retrospectively without knowledge of
patient details and irrespective of the number of glomeruli in the specimen. On a representative
section, usually stained using periodic acid–methenamine silver, the total number of glomeruli
was counted. Each glomerulus was put into 1 of 5 categories, which were summed for each
biopsy and expressed as percentages of the total number of glomeruli: normal glomeruli,
globally sclerosed glomeruli, glomeruli with ischemic shrinkage, glomeruli with active
vasculitic lesions, and glomeruli with healed vasculitic lesions. Active vasculitic lesions were
defined as segmental or global areas of combinations of thrombosis, disruption of capillary
basement membranes, and cells in Bowman space. Healed vasculitic lesions were defined as
those in which areas of fibrosis included the glomerular tuft and Bowman space. Active and
healed segmental lesions usually were sharply demarcated from the rest of the glomerulus.
Lesions that were healing were arbitrarily assigned to active or healed categories based on the
relative amounts of cells and fibers in the lesions. Arteritis or arteriolitis was diagnosed by the
finding of fibrinoid necrosis and/or an inflammatory infiltrate in the wall of relevant vessels.
The index of chronic damage was measured in each biopsy specimen as previously
described. Briefly, using a digital image of renal cortex, atrophic areas were outlined by
freehand and their cross-sectional areas were measured in pixels. Atrophic areas were defined
as those containing any combination of globally sclerosed glomeruli, shrunken tubules with
thickened basement membranes, interstitial fibrosis, cysts, and occluded vessels. The cortex
in the image then was outlined and its area was measured. This was repeated until all cortex
was measured. The total of atrophic areas was expressed as a percentage of total cortical area
and called the index of chronic damage. This could range from 0% in a kidney without no
chronic damage to 100% in a completely atrophic kidney.
Previously, the limits of interobserver agreement for the index of chronic damage were
determined to be between 0.88 (95% confidence interval [CI], 0.82-0.93) and 1.22 (95% CI,
1.15-1.30), with a mean agreement of 1.03 (95% CI, 0.99-1.07). The limits of intraobserver
agreement were 0.79 (95% CI, 0.74-0.85) and 1.29 (95% CI, 1.20-1.39), with a mean of 1.01
(95% CI, 0.97-1.06). The definition of the index of chronic damage is listed in Box 1.
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Data Analysis
Analysis was performed using SPSS for Windows, version 14 (SPSS Inc,
www.spss.com/uk/). Univariable and multivariable survival analyses were performed initially
using stepwise Cox regression with creatinine level as a continuous variable. Histologic
parameters were divided into groups of 1 standard deviation to make hazard ratios more
meaningful. When > 1 biopsy was performed, only the initial presenting biopsy specimen was
used in these analyses. Time origin (t = 0) was the value of the parameter at the initial presenting
biopsy. If a patient did not progress to ESRD, they were censored at either death or last follow-
up, with the latter at least 2 years after the initial presentation. Correlations of pathologic
variables with serum creatinine concentrations at biopsy or ANCA status were computed using
Spearman rank correlation for nonparametric variables. The C statistic is the proportion of
pairs of individuals for which the model correctly predicted which individual had the shorter
time to event (pairs for which this is not known were excluded from the calculation).
In analysis of the repeated biopsy data, when there were > 2 biopsies available, only the earliest
and most recent were analyzed. Patients underwent a repeated biopsy because of either a
suspected disease flare or inadequate response to therapy. As such, this group is subject to
selection bias. Rates of changes in the index of chronic damage, percentage of normal
glomeruli, and serum creatinine concentration were calculated by dividing the change in each
parameter between the 2 biopsies by the time separating the 2 samples.
Further analysis of the initial biopsy data was performed by dividing the population into
quartiles of percentage of normal glomeruli. Quartile division was not possible for the index
of chronic damage because a large number of biopsy specimens showed an index of 0%.
Therefore, this parameter was divided into 4 groups: all biopsy specimens with an index of 0%
and the remainder of the population divided into tertiles. Differences between groups in
progression to ESRD were calculated using stepwise Cox regression. A likelihood ratio
comparing goodness of fit was used to test for interactions between creatinine level and 2
histologic variables (percentage of normal glomeruli and index of chronic damage) in
multivariable analysis of the entire population.
Results
Baseline Characteristics and Overall Outcomes
During the study period, 390 patients were given a diagnosis of pauci-immune necrotizing
glomerulonephritis. Of these, 90 patients underwent > 1 kidney biopsy, but only initial biopsies
were included in the analysis unless otherwise stated (see Repeated Biopsy Data in this section).
Median age at initial biopsy was 64 years (range, 15-90 years), and median serum creatinine
level at biopsy was 3.86 mg/dL (range, 0.52-20.6 mg/dL). Follow-up was until patient death
or for at least 2 years from the initial biopsy for surviving patients, with median follow-up of
166 weeks (range, 1 day-1,256 weeks). During follow-up, 214 (55%) patients died: 89 (23%)
during the first year, 149 (40%) by 5 years, and 184 (49%) by 10 years. Permanent renal
replacement therapy was required in 87 (22%) patients: 54 (14%) in the first year, 67 (18%)
by 5 years, and 76 (21%) by 10 years.
In the present cohort, the median index of chronic damage was 10% (range, 0%-94%). Baseline
characteristics and outcomes for patients segregated by index of chronic damage values are
listed in Table 1. Median percentage of normal glomeruli was 31% (range, 0%-100%), and
median percentage of glomeruli with active lesions was 19% (range, 0%-100%). ANCA
immunofluorescence data were available for 230 patients. Perinuclear ANCA (pANCA)-
positive patients were significantly older at presentation than cytoplasmic ANCA (cANCA)
patients (median age, 67 vs 57 years; P < 0.001). The mean index of chronic damage was
significantly higher in pANCA-positive patients (31.17% vs 19.55%; P = 0.003), which
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remained significant after correction for age (P = 0.04). Furthermore, pANCA-positive patients
had a higher percentage of globally sclerosed glomeruli (P < 0.001), whereas cANCA-positive
patients showed more glomeruli with active lesions (P = 0.001) and arteritis (P = 0.03).
Mortality
Death was predicted by serum creatinine level at biopsy (hazard ratio, 1.12; 95% CI, 1.09-1.16;
P < 0.001) and age (hazard ratio, 1.05; 95% CI, 1.04-1.07; P < 0.001), but not by any histologic
variable examined. An association between pANCA versus cANCA positivity and increased
mortality (P = 0.03) was not significant after correction for age.
Only 2 patients died of active vasculitis > 3 months after diagnosis. During the entire study
period, major causes of death were as follows: active vasculitis or complications of therapy
within 3 months of diagnosis, 45 (24%); ischemic heart disease or stroke, 42 (23%); infection
> 3 months from diagnosis, 41 (22%); chronic kidney disease, 32 (17%); malignancy 20 (11%);
and gastrointestinal disease, 6 (3%).
Using data obtained from the UK Office of National Statistics for age-standardized death rates
per 1,000 population in 2002, the calculated standardized mortality ratio for this patient cohort
was 4.74 (95% CI, 3.62-6.32) with an odds ratio of 9.32 (95% CI, 6.45-13.47).
Correlation of Variables With Serum Creatinine Concentration at Biopsy
There were significant correlations between serum creatinine level at biopsy and age (r = 0.273;
P < 0.001), index of chronic damage (r = 0.263; P < 0.001), percentage of normal glomeruli
(r = −0.583; P < 0.001), percentage of glomeruli with active lesions (r = 0.368; P < 0.001),
and percentage of globally sclerosed glomeruli (r = 0.192; P < 0.001). There was no correlation
between serum creatinine level at biopsy and either ANCA subtype (r = 0.033; P = 0.6) or
presence of arteritis (r = −0.51; P = 0.4).
Progression to ESRD
Using univariable analysis, serum creatinine level at biopsy and all histologic variables
examined significantly correlated with ESRD both at 1 year and throughout the duration of the
study. In contrast, age was not associated with ESRD (Table 2). In multivariable analysis,
serum creatinine level at biopsy and percentage of normal glomeruli were independent
predictors of ESRD (Table 3). This was reflected in C statistics for Cox regression: C = 0.8
for creatinine level alone and C = 0.83 for creatinine level with percentage of normal glomeruli.
No significant interaction was shown between serum creatinine level and either percentage of
normal glomeruli or index of chronic damage. Considering those for whom ANCA
immunofluorescence was known, there was no difference in progression to ESRD between
pANCA- and cANCA-positive patients (P = 0.9).
Dividing the index of chronic damage into groups suggested a threshold effect because kidney
outcome did not differ significantly for the first 3 groups. However, the fourth group (≥48%
chronic damage) had a significantly worse kidney outcome (Table 1). A threshold effect also
was apparent for normal glomeruli because progression to ESRD did not differ significantly
for the third (32%-65%) compared with the fourth quartile (≥66%), whereas progression to
ESRD was significantly more frequent for the first (0%-8%) and second (9%-31%) quartiles
(ie, biopsy specimens showing the least normal glomeruli; Table 4). Conversely, the second,
third, and fourth quartiles of normal glomeruli had better kidney outcomes than the first quartile
(≤8%; not shown).
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Repeated Biopsy Data
Data confirm that histologic variables measured in a first biopsy specimen are associated with
ESRD across the entire patient cohort. In this study, 90 patients underwent > 1 biopsy,
providing an opportunity to examine the association of changes in histologic variables with
outcomes of individual patients. Median time between biopsies was 397 days (range, 9-6,666
days). Comparing patients in the subgroup that developed ESRD (n = 40) with those who did
not (n = 50), second biopsy specimens from those reaching ESRD showed a higher median
index of chronic damage (66.5% vs 29.0%) and decreased median percentage of normal
glomeruli (6.0% vs 20.0%). In multivariable analysis, only creatinine level at the second biopsy
(median, 7.52 mg/dL in patients developing ESRD vs 2.59 mg/dL in those retaining
independent kidney function) and rate of change in index of chronic damage (0.11%/d vs
0.009%/d) were associated with progression to ESRD (Table 5). For the entire subgroup,
median rate of change in the index of chronic damage was +10.76%/y (Fig 1).
Discussion
The prognosis for patients with pauci-immune necrotizing glomerulonephritis has improved
with therapeutic immunosuppression. Nonetheless, by 5 years, 18% of patients in this cohort
required permanent renal replacement therapy and 40% had died. Previous studies also have
reported high mortality in patients with systemic vasculitis. Allowing for the limitations of
accuracy in death certification, the high rate of infection-related mortality in this study supports
the hypothesis that adverse effects of therapy contribute to poor outcome and emphasizes the
advantage of identifying patients with salvageable kidney function.
Previous smaller studies have reported more long-term damage in pANCA/myeloperoxidase-
ANCA–positive versus cANCA/proteinase 3–ANCA patients, but similar outcomes. Our study
supports this concept and indicates that ANCA subtype should not influence treatment. The
basis of the difference in pathologic features between the 2 subgroups is uncertain and could
reflect either earlier diagnosis in patients with cANCA (perhaps because of prominent
extrarenal symptoms) or genuinely divergent disease characteristics.
Other studies of kidney biopsies in patients with systemic vasculitis (Table 6) have involved
relatively complex scoring systems. Moreover, the consistency of biopsy interpretation in
patients with pauci-immune necrotizing glomerulonephritis is uncertain because although
quantitative measurements of glomerular morphologic characteristics show satisfactory
agreement, interobserver agreement for dichotomous variables used to score tubulointerstitial
damage appears to be poor. Similarly, the reproducibility and predictive value of
semiquantitative chronicity scores in patients with lupus nephritis is controversial, and their
applicability outside specialist referral centers is disputed. More recently, computer-assisted
morphometric assessment of lupus nephritis has been described and has predicted outcome in
a relatively small cohort (n = 48).
Our study comprises a large cohort with a unified diagnosis and extended follow-up. Serum
creatinine level at biopsy correlated with glomerular morphologic characteristics, as previously
reported, and with index of chronic damage. Furthermore, both glomerular morphologic
characteristics and the index of chronic damage significantly correlated with kidney outcome.
Multivariable analysis showed serum creatinine level at biopsy and percentage of normal
glomeruli in the initial biopsy specimen to be independent predictors of ESRD. As in other
studies, no pathologic features predicted death, which was predicted by age and serum
creatinine level at biopsy.
In a subgroup of patients undergoing repeated biopsy (performed in the context of suspected
disease flare or inadequate response to therapy), accelerated change in the index of chronic
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damage was associated independently with kidney outcome, whereas percentage of normal
glomeruli was not. Previous studies using repeated biopsy data have shown progression of
chronic damage (semiquantitatively scored) or an increase in global glomerulosclerosis, but
not an association with progression to ESRD. The index of chronic damage might provide
additional information because it reflects irreversible damage in the tubulo-interstitial and
vascular compartments, as well as glomerular scarring. Furthermore, the index may be more
meaningful when a biopsy specimen contains only a few glomeruli. We have already reported
that the index is an indicator of progression to ESRD in patients with lupus nephritis and in a
heterogeneous cohort of patients with chronic kidney disease (predominantly immunoglobulin
A nephropathy and Henoch-Schönlein nephritis).
There are several limitations to our study. It was a retrospective analysis with uncontrolled
differences between patient groups, mainly in treatment regimens. ANCA specificity was
analyzed using indirect immunofluorescence rather than enzyme-linked immunosorbent assay
and was recorded in only 59% (230/390) of patients, reflecting the available data set, rather
than an unusually high proportion of truly ANCA-negative cases. In addition, there has been
only limited assessment of the extent of inter- and intraobserver agreement using the index of
chronic damage. Previous studies involving a small number of pathologists have shown that
the degree of variation is low, but this merits confirmation. Furthermore, repeated biopsy
analyses could be affected by selection bias.
Although histologic variables can correlate with or predict kidney outcome, histology has not
yet been used to direct treatment in a trial setting. An analysis of biopsies from the MEPEX
(methyl prednisolone or plasma exchange for severe renal vasculitis) trial concluded that for
patients receiving plasma exchange, the chance of kidney recovery always exceeds the risk of
therapy-related death regardless of the severity or nature of histopathologic change. This
suggests that treatment should not be restricted for patients who present with severely decreased
kidney function. Nevertheless, the likelihood of reaching ESRD or dying is substantial using
any current treatment, and death from complications of therapy is well recognized.
Accordingly, the search for robust tools that could support treatment decisions (either limitation
when it is futile or intensification when the risk of inadequate response is greater) remains
relevant.
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Table 2
Univariable Analyses of Progression to ESRD
ESRD at 1 Year ESRD During Total Follow-up
HR 95% CI P HR 95% CI P
Age (/1 SD) 1.32 0.97-1.78 0.07 1.15 0.92-1.45 0.2
Initial SCr (/1
mg/dL)
1.26 1.19-1.33 <0.001 1.24 1.18-1.29 <0.001
% Normal
glomeruli (/1
SD)
0.27 0.15-0.49 <0.001 0.34 0.23-0.49 <0.001
% Active
glomeruli (/1
SD)
1.59 1.24-2.07 0.001 1.47 1.20-1.82 <0.001
% Sclerosed
glomeruli (/1
SD)
1.46 1.13-1.88 0.003 1.54 1.27-1.87 <0.001
Index of
chronic
damage (/1
SD)
1.72 1.32-2.24 <0.001 1.78 1.42-2.22 <0.001
Note: SCr is treated as a continuous variable; other variables are divided into groups by 1 SD, which corresponds to 16 years for age, 33% for percentage
of normal glomeruli, 30% for percentage of active glomeruli, 21% for percentage of sclerosed glomeruli, and 30% for index of chronic damage.
Abbreviations: CI, confidence interval; ESRD, end-stage renal disease; HR, hazard ratio; SCr, serum creatinine; SD, standard deviation.
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Table 3
Multivariable Analyses of Progression to ESRD
ESRD at 1 Year ESRD During Total Follow-up
HR 95% CI P HR 95% CI P
SCr at presentation
(mg/dL)
1.21 1.14-1.28 <0.001 1.19 1.13-1.25 <0.001
% Normal glomeruli 0.42 0.21-0.82 0.01 0.47 0.31-0.71 <0.001
Note: Multivariable analyses were performed using forward stepwise Cox regression. Variables used were age; index of chronic damage; percentages
of normal, active, and sclerosed glomeruli (all divided by standard deviation); and SCr level at presentation (milligrams per deciliter).
Abbreviations: CI, confidence interval; ESRD, end-stage renal disease; HR, hazard ratio; SCr, serum creatinine.
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Table 4
Progression to End-Stage Renal Disease by Quartiles of Percentage of Normal Glomeruli
Percentage of Normal Glomeruli
in Quartile
Progression to End-Stage Renal Disease
Quartile Range Median % P Relative Risk (95%
confidence interval)
1 0-8 0 46.6 <0.001 10.53 (4.71-23.54)
2 9-31 17 22.8 0.001 4.39 (1.86-10.40)
3 32-65 46 14.1 0.1 1.99 (0.80-5.01)
4 67-100 86.5 7.5 — 1.00 (reference)
Note: Global P < 0.001.
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Table 5
Univariable and Multivariable Analyses of Progression to End-Stage Renal Disease in Patients Undergoing > 1
Renal Biopsy
Univariable Analysis Multivariable Analysis
Hazard Ratio (95%
confidence interval)
P Hazard Ratio (95%
confidence interval)
P
Serum creatinine at
biopsy 1 (/1 mg/dL)
1.16 (1.08-1.25) <0.001
Serum creatinine at
biopsy 2 (/1 mg/dL)
1.44 (1.29-1.61) <0.001 1.42 (1.26-1.60) <0.001
Index of chronic
damage at biopsy
1 (/1 SD)
1.35 (0.89-2.04) 0.2
Index of chronic
damage at biopsy
2 (/1 SD)
2.45 (1.73-3.61) <0.001
Percentage of
normal glomeruli at
biopsy 1 (/1 SD)
0.42 (0.26-0.69) 0.001
Percentage of
normal glomeruli at
biopsy 2 (/1 SD)
0.48 (0.25-0.93) 0.03
Rate of change in
serum creatinine
(mg/dL/d) (/1 SD)
0.94 (0.85-1.03) 0.2
Rate of change in
index of chronic
damage (%/d) (/1
SD)
3.51 (1.92-6.42) <0.001 2.08 (1.11-3.89) 0.02
Rate of change in
percentage of
normal glomeruli
(%/d) (/1 SD)
1.47 (0.80-2.86) 0.2
Note: All variables were used in multivariable stepwise Cox regression.
Abbreviation: SD, standard deviation.
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Table 6
Summary of Related Studies
Study No. of Participants/Follow-up Outcome Measures Resultsa
Bajema et al(EC/
BCR Project for
ANCA assay
standardization)
157/1 y Correlations with
SCr at 1 y
% normal glomeruli (−); diffuse
interstitial infiltrates, tubular
necrosis, % globally sclerotic
glomeruli, tubular atrophy (+)
Aasarod et al
(retrospective,
Wagener
granulomatosis
only)
94/median, 42.5 mo Correlations with
SCr at 1 y
% glomeruli with
crescents, % normal
glomeruli (−)
Multivariable analysis
showed only % normal
glomeruli associated with
development of ESRD
Hauer et al
(CYCAZAREM
trial; SCr < 500
μmol/L at entry)
96/18 mo GFR at 18 mo 39 pathologic features,
GFR at entry (+);
interstitial fibrosis, global
glomerulosclerosis,
tubular atrophy (−)
In stepwise multiple
regression, predictors were
GFR at entry, % fibrinoid
necrosis, % segmental
crescents (+)
Vergunst et al(EC/
BCR Project for
ANCA assay
standardization)
160/1 y GFR at 1 y 16 pathologic features
Stepwise regression
analysis creating formula
to predict GFR at 1 y
including initial GFR,
presence of normal
glomeruli and fibrinoid
necrosis, and age
Neumann et al
(retrospective)
67 SCr; modified lupus
nephritis activity,
chronicity scoring
system
At 1 y: activity index,
chronicity index (+); %
normal glomeruli (−)
At 4 y: chronicity index
(+), % normal glomeruli
(−)
Hogan et al
(prospective)
340/median, 49 mo Treatment resistance associated
with increased chronicity score
of initial biopsy
De Lind van
Wijngaarden et al
(MEPEX; SCr >
500 μmol/L at
entry)
100/1 y GFR at 12 mo Normal glomeruli (+); tubular
atrophy, global
glomerulosclerosis, interstitial
fibrosis (−)
Abbreviations: (+), positive correlation; (−), inverse correlation; ANCA, antineutrophil cytoplasmic antibody; CYCAZAREM, cyclophosphamide
versus azathioprine for remission in generalized vasculitis; EC/BCR, European Commission/Bureau Communautaire de Référence; ESRD, end-stage
renal disease; GFR, glomerular filtration rate; MEPEX, methyl prednisolone or plasma exchange for severe renal vasculitis; SCr, serum creatinine.
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